Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;78(7):880-882.
doi: 10.1001/jamaneurol.2021.1364.

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Zoé L E van Kempen  1 , Eva M M Strijbis  1 , Marissa M C T Al  1 , Maurice Steenhuis  2 , Bernard M J Uitdehaag  1 , Theo Rispens  2 , Joep Killestein  1
Affiliations

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Zoé L E van Kempen et al. JAMA Neurol. .

Abstract

This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr van Kempen reports a grant from Dutch MS Research Foundation (grant 20-005 PP) during the conduct of the study. Dr Uitdehaag reports personal fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva consultancy fees outside the submitted work. Dr Rispens reports grants from Netherlands Organisation for Health Research and Development (ZonMw) during the conduct of the study. Dr Killestein reports a grant from Dutch MS Research Foundation (grant 20-005 PP) during the conduct of the study; personal fees from Biogen, Genzyme, Merck, Novartis, and Roche; and grants from Teva, Biogen, Genzyme, Merck, Novartis, and Roche, outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response in Patients With Multiple Sclerosis With Positive Results on Polymerase Chain Reaction (PCR) and Antibody Testing
A, Time between the positive PCR (at month 0) and the SARS-CoV-2 total antibody test. In 4 patients, no SARS-CoV-2 antibodies could be detected. None were lymphopenic (<1000 cells per microliter; to convert to cells × 109 per liter, multiply by 0.001) in testing in the 2 months prior to the start of COVID-19 complaints. The patient taking ocrelizumab was B-cell depleted prior to COVID-19 and had received 4 cycles of ocrelizumab. B, SARS-CoV-2 antibody response in patients with positive results on PCR and/or antibody testing who were receiving different disease-modifying therapies. The maximum response that could be measured was 2.5 normalized optical density (nOD) units, with a cutoff of 0.1 for seropositivity. The 2 patients treated with alemtuzumab received their last course 43 and 29 months prior to SARS-CoV-2 antibody sampling, respectively. One patient with an autologous stem cell transplant (aSCT) was treated 10 months prior to SARS-CoV-2 antibody sampling.
See this image and copyright information in PMC

Comment in

References

    1. Vogelzang EH, Loeff FC, Derksen NIL, et al. ; Amsterdam University Medical Center COVID-19 Biobank Study Group . Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and nonhospitalized patients with COVID-19. J Immunol. 2020;205(12):3491-3499. doi:10.4049/jimmunol.2000767 - DOI - PubMed
    1. Lucchini M, Bianco A, Del Giacomo P, De Fino C, Nociti V, Mirabella M. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? a case report. Mult Scler Relat Disord. 2020;44:102323. doi:10.1016/j.msard.2020.102323 - DOI - PMC - PubMed
    1. Maillart E, Papeix C, Lubetzki C, Roux T, Pourcher V, Louapre C. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Mult Scler Relat Disord. 2020;46:102482. doi:10.1016/j.msard.2020.102482 - DOI - PMC - PubMed
    1. Meca-Lallana V, Aguirre C, del Río B, Cardeñoso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. Mult Scler Relat Disord. 2020;44:102306. doi:10.1016/j.msard.2020.102306 - DOI - PMC - PubMed
    1. Zabalza A, Cárdenas-Robledo S, Tagliani P, et al. . COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol. 2020. - PubMed

Publication types

Substances